Clinical Utility of ctDNA in the Treatment of Oligometastatic Disease
NCT07426250
Summary
This prospective observational study investigates the clinical utility of circulating tumor DNA (ctDNA) in patients with oligometastatic disease (OMD) undergoing definitive-intent local ablative treatment (LAT). The study aims to evaluate ctDNA as a prognostic and response biomarker before, during, and after LAT across cancer types and treatment modalities. Serial plasma samples and archival tumor tissue will be analyzed to assess ctDNA detection rates, elimination patterns, minimal residual disease, and association with recurrence, progression, and survival outcomes.
Eligibility
Inclusion Criteria: * Metastatic spread from histopathological diagnosed solid cancer * Planned for LAT (local ablative therapy) for OMD (oligometastatic disease) * ≥ 18 years * Written and oral consent Exclusion Criteria: * Other cancer disease within 5 years * Conditions that will contraindicate blood samples
Conditions2
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07426250